Cargando…

In vitro activity of rezafungin against common and rare Candida species and Saccharomyces cerevisiae

BACKGROUND: Rezafungin is a novel echinocandin with excellent activity against common Candida species; however, limited data are available regarding rare Candida species. METHODS: We determined the in vitro susceptibility of 689 clinical isolates of 5 common and 19 rare Candida species, as well as S...

Descripción completa

Detalles Bibliográficos
Autores principales:	Tóth, Zoltán, Forgács, Lajos, Locke, Jeffrey B, Kardos, Gábor, Nagy, Fruzsina, Kovács, Renátó, Szekely, Adrien, Borman, Andrew M, Majoros, László
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2019
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6857195/ https://www.ncbi.nlm.nih.gov/pubmed/31539426 http://dx.doi.org/10.1093/jac/dkz390

Ejemplares similares

Comparison of In Vitro Killing Activity of Rezafungin, Anidulafungin, Caspofungin, and Micafungin against Four Candida auris Clades in RPMI-1640 in the Absence and Presence of Human Serum
por: Kovács, Renátó, et al.
Publicado: (2021)

Relative Frequency of Paradoxical Growth and Trailing Effect with Caspofungin, Micafungin, Anidulafungin, and the Novel Echinocandin Rezafungin against Candida Species
por: Tóth, Zoltán, et al.
Publicado: (2020)

Comparison of in vivo pathogenicity of four Candida auris clades in a neutropenic bloodstream infection murine model
por: Forgács, Lajos, et al.
Publicado: (2020)

Efficacy of humanized single large doses of caspofungin on the lethality and fungal tissue burden in a deeply neutropenic murine model against Candida albicans and Candida dubliniensis
por: Prépost, Eszter, et al.
Publicado: (2019)

In vitro and in vivo Effect of Exogenous Farnesol Exposure Against Candida auris
por: Nagy, Fruzsina, et al.
Publicado: (2020)

The Neosartorya fischeri Antifungal Protein 2 (NFAP2): A New Potential Weapon against Multidrug-Resistant Candida auris Biofilms
por: Kovács, Renátó, et al.
Publicado: (2021)

In Vivo Efficacy of Amphotericin B against Four Candida auris Clades
por: Forgács, Lajos, et al.
Publicado: (2022)

Unpredictable In Vitro Killing Activity of Amphotericin B against Four Candida auris Clades
por: Papp, Zoltán, et al.
Publicado: (2021)

In Vitro Killing Activities of Anidulafungin and Micafungin with and without Nikkomycin Z against Four Candida auris Clades
por: Adnan, Awid, et al.
Publicado: (2023)

Total transcriptome analysis of Candida auris planktonic cells exposed to tyrosol
por: Balla, Noémi, et al.
Publicado: (2023)

Transcriptional Profiling of the Candida auris Response to Exogenous Farnesol Exposure
por: Jakab, Ágnes, et al.
Publicado: (2021)

The Role of Uniform Meropenem Usage in Acinetobacter baumannii Clone Replacement
por: Balázs, Bence, et al.
Publicado: (2021)

Synergistic Interaction of Caspofungin Combined with Posaconazole against FKS Wild-Type and Mutant Candida auris Planktonic Cells and Biofilms
por: Balla, Noémi, et al.
Publicado: (2022)

The In Vitro Activity of Fluconazole, Amphotericin B and Echinocandins Against Cyberlindnera fabianii Planktonic Cells and Biofilms
por: Tóth, Zoltán, et al.
Publicado: (2022)

Faecal Carriage of Carbapenem-Resistant Acinetobacter baumannii: Comparison to Clinical Isolates from the Same Period (2017–2019)
por: Balázs, Bence, et al.
Publicado: (2022)

Fungal Quorum-Sensing Molecules: A Review of Their Antifungal Effect against Candida Biofilms
por: Kovács, Renátó, et al.
Publicado: (2020)

Heme Oxygenase-1 (HMX1) Loss of Function Increases the In-Host Fitness of the Saccharomyces ‘boulardii’ Probiotic Yeast in a Mouse Fungemia Model
por: Imre, Alexandra, et al.
Publicado: (2022)

Comparative Pathogenicity of United Kingdom Isolates of the Emerging Pathogen Candida auris and Other Key Pathogenic Candida Species
por: Borman, Andrew M., et al.
Publicado: (2016)

Time-Kill Kinetics of Rezafungin (CD101) in Vagina-Simulative Medium for Fluconazole-Susceptible and Fluconazole-Resistant Candida albicans and Non-albicans Candida Species
por: Locke, Jeffrey B., et al.
Publicado: (2018)

Rezafungin treatment in mouse models of invasive candidiasis and aspergillosis: Insights on the PK/PD pharmacometrics of rezafungin efficacy
por: Miesel, Lynn, et al.
Publicado: (2019)

Evolution of the Gram-Negative Antibiotic Resistance Spiral over Time: A Time-Series Analysis
por: Tóth, Hajnalka, et al.
Publicado: (2021)

Regulatory circuitry governing morphogenesis in Saccharomyces cerevisiae and Candida albicans
por: Shapiro, Rebecca S., et al.
Publicado: (2012)

Overcoming the Resistance Hurdle: Pharmacokinetic-Pharmacodynamic Target Attainment Analyses for Rezafungin (CD101) against Candida albicans and Candida glabrata
por: Bader, Justin C., et al.
Publicado: (2018)

2115. Rezafungin Activity against Invasive Candidiasis Isolates Globally: Results from the 2022 Rezafungin Surveillance Program
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Expanded Access Use of Rezafungin for Salvage Therapy of Invasive Candida glabrata Infection: A Case Report
por: Adeel, Alina, et al.
Publicado: (2021)

Population Pharmacokinetics of Rezafungin in Patients with Fungal Infections
por: Rubino, Christopher M., et al.
Publicado: (2021)

1731. Rezafungin Activity against Candida spp. and Aspergillus spp. Isolates Causing Invasive Infections Worldwide in 2021
por: Carvalhaes, Cecilia G, et al.
Publicado: (2022)

Exploring the substrate scope of ferulic acid decarboxylase (FDC1) from Saccharomyces cerevisiae
por: Nagy, Emma Zsófia Aletta, et al.
Publicado: (2019)

Candida albicans Hexokinase 2 Challenges the Saccharomyces cerevisiae Moonlight Protein Model
por: Laurian, Romain, et al.
Publicado: (2021)

Virulence Factors and in-Host Selection on Phenotypes in Infectious Probiotic Yeast Isolates (Saccharomyces ‘boulardii’)
por: Imre, Alexandra, et al.
Publicado: (2021)

Evaluation of the efficacy of rezafungin, a novel echinocandin, in the treatment of disseminated Candida auris infection using an immunocompromised mouse model
por: Hager, Christopher L, et al.
Publicado: (2018)

1390. Pharmacokinetic-Pharmacodynamic (PK-PD) Target Attainment Analyses to Support Rezafungin (RZF) Dose Selection in Treatment of Candida
por: Lakota, Elizabeth A, et al.
Publicado: (2018)

2389. Effect of Rezafungin on QT Interval in Healthy Subjects
por: Flanagan, Shawn, et al.
Publicado: (2018)

The Antifungal Pipeline: Fosmanogepix, Ibrexafungerp, Olorofim, Opelconazole, and Rezafungin
por: Hoenigl, Martin, et al.
Publicado: (2021)

982. Effect of Hepatic Impairment on the Safety and Pharmacokinetics of Rezafungin
por: Huguet, Jade, et al.
Publicado: (2021)

1947. Activity of Rezafungin against Echinocandin–Non-wild type C. glabrata Clinical Isolates from the Rezafungin Surveillance Program (2014–2021)
por: Carvalhaes, Cecilia G, et al.
Publicado: (2023)

Antifungal Activity of an Original Amino-Isocyanonaphthalene (ICAN) Compound Family: Promising Broad Spectrum Antifungals
por: Nagy, Miklós, et al.
Publicado: (2020)

The TORC2-Dependent Signaling Network in the Yeast Saccharomyces cerevisiae
por: Roelants, Françoise M., et al.
Publicado: (2017)

Multicopper Oxidases in Saccharomyces cerevisiae and Human Pathogenic Fungi
por: Chakraborty, Tanmoy, et al.
Publicado: (2020)

Genome adaptation to chemical stress: clues from comparative transcriptomics in Saccharomyces cerevisiae and Candida glabrata
por: Lelandais, Gaëlle, et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_bqo1hemgr3ckuak40312iujhd2